944256-23-9

Basic information

• Product Name: tert-butyl (3-(methoxy(methyl)carbamoyl)phenyl)carbamate
• Synonyms: tert-butyl (3-(methoxy(methyl)carbamoyl)phenyl)carbamate
• CAS NO: 944256-23-9
• Molecular Weight: 280.324
• Mol File: 944256-23-9.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (3-(methoxy(methyl)carbamoyl)phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3-(methoxy(methyl)carbamoyl)phenyl)carbamate(944256-23-9)
• EPA Substance Registry System: tert-butyl (3-(methoxy(methyl)carbamoyl)phenyl)carbamate(944256-23-9)

Safety Data

• Hazardous Substances Data: 944256-23-9(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 99-05-8 meta-aminobenzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 111331-82-9 3-[(tert-butoxycarbonyl)amino]benzoic acid 

Downstream Products

• 944256-24-0 C₂₀H₂₃NO₅ 

Relevant articles and documents

Total Synthesis of cis-Clavicipitic Acid from Asparagine via Ir-Catalyzed C-H bond Activation as a Key Step

4-Substituted tryptophan derivatives and the total synthesis of cis-clavicipitic acid were achieved in reactions in which Ir-catalyzed C-H bond activation was a key step. The starting material for these reactions is asparagine, which is a cheap natural amino acid. The reductive amination step from the 4-substituted tryptophan derivative gave cis-clavicipitic acid with perfect diastereoselectivity.

Urotensin II receptor antagonists

This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.

UROTENSIN II RECEPTOR ANTAGONISTS

The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.